OneSource Specialty Pharma gets in-principle approval for Unit II expansion under KIP 2025–30
OneSource Specialty Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Karnataka Government approved Unit II expansion incentives in 67th SHLCC meeting on April 13, 2026
- Received Government Order No. CI 120 SPI 2026 dated May 12, 2026, on May 15, 2026
- Expansion at Obadenahalli, KIADB Industrial Area, Bengaluru Rural District to boost manufacturing capacity
Why it's rated notable: The filing gives an in-principle approval of incentives and concessions for the Unit II expansion but states no investment or incentive amount, so the level rests on the approval's stage and the described expansion.
Original filing
General-Update
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from OneSource Specialty Pharma
- Acquisition / mergerNotableOneSource Specialty Pharma Limited withdraws current merger plan with Steriscience entities
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.